Drug Type Small molecule drug |
Synonyms SFA006 |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization SFA Therapeutics, Inc.Startup |
Active Organization SFA Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Distress Syndrome | Phase 1 | US | SFA Therapeutics, Inc.Startup | 01 Mar 2022 |
Cytokine Release Syndrome | Preclinical | US | SFA Therapeutics, Inc.Startup | 01 Mar 2022 |
Post Acute COVID 19 Syndrome | Preclinical | US | SFA Therapeutics, Inc.Startup | 01 Mar 2022 |
Sepsis | Preclinical | US | SFA Therapeutics, Inc.Startup | 01 Mar 2022 |